Natera (NTRA) is back in focus after new transplant data at the 2026 American Transplant Congress linked its Prospera test to future adverse outcomes even when biopsies are negative, alongside fresh collaboration headlines.

The recent Prospera data and new transplant collaborations have arrived alongside a strong run in Natera’s shares, with a 30-day share price return of 12.93% and a 1-year total shareholder return of 34.65%. The 3-year total shareholder return above 7x points to momentum that remains firmly intact.

If you are looking for more ideas in a similar vein to Natera’s use of AI in healthcare, this is a good moment to scan the 40 healthcare AI stocks

With Natera’s shares up strongly over 1 and 3 years, and with fresh Prospera data and new transplant collaborations, these developments now sit against richer expectations. Is the stock still undervalued, or are markets already pricing in future growth?

Most Popular Narrative: 11.3% Undervalued

Natera’s most followed narrative points to a fair value of about $260.89 versus the last close at $231.41, framing the Prospera data and transplant news against an already optimistic long term earnings path.

Investment in new product launches (e.g., Fetal Focus NIPT, Signatera Genome, AI-based biomarkers) and a robust R&D pipeline positions Natera to capture growth from long-term trends in personalized medicine and early detection, underpinning future revenue expansion.

Curious what has to happen in Natera’s income statement to support that fair value gap? The narrative leans on faster revenue compounding, higher margins, and a richer future earnings multiple. The exact mix of those levers is where the story gets interesting.

Result: Fair Value of $260.89 (UNDERVALUED)

However, the Natera story could look very different if key clinical trials disappoint or if reimbursement and regulatory approvals arrive more slowly than analysts currently expect.

Another View: Natera On Sales Based Valuation

The SWS DCF model suggests Natera is trading at a steep discount to estimated future cash flows, with a fair value of about $500.01 versus the last close at $231.41. That points to undervaluation, but do the cash flow assumptions justify such a wide gap?

Next Steps

If this mix of optimism and caution around Natera leaves you undecided, now is a good time to review the details yourself and weigh both sides, especially as the company carries 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond Natera?

If Natera has sharpened your interest in focused stock research, now is the time to widen your net and hunt for other potential opportunities using targeted screens.

• Seek out potential mispricing by scanning 45 high quality undervalued stocks and see which companies currently sit at the crossroads of quality and discounted expectations.
• Prioritise resilience by reviewing 66 resilient stocks with low risk scores so you can focus on stocks with steadier risk profiles when markets feel less forgiving.
• Hunt for future standouts through the screener containing 19 high quality undiscovered gems and avoid missing lesser known companies with strong underlying fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.